The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Highlights in CLL from ASH 2024
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares her highlights in the field of chronic lymphocytic leukemia (CLL) from the 2024 ASH Annual Meeting, commenting on the widespread excitement over the Phase III AMPLIFY study (NCT03836261), which is investigating acalabrutinib and venetoclax (AV) with or without the addition of obinutuzumab (AVO). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The top highlight the majority would say is the AMPLIFY study, which is being presented comparing as primary endpoint, acalabrutinib plus venetoclax versus FCR or BR in patients who can tolerate at least BR above the age of 65 years. And there’s a third arm with acalabrutinib, venetoclax and obinutuzumab. And then there’s a superiority of acalabrutinib-venetoclax versus FCR-BR...
The top highlight the majority would say is the AMPLIFY study, which is being presented comparing as primary endpoint, acalabrutinib plus venetoclax versus FCR or BR in patients who can tolerate at least BR above the age of 65 years. And there’s a third arm with acalabrutinib, venetoclax and obinutuzumab. And then there’s a superiority of acalabrutinib-venetoclax versus FCR-BR. We expect that soon we will have another oral doublet combination being approved in CLL, which leaves them with a suspected side effect profile of ibrutinib versus acalabrutinib and the choice between those two different agents. There’s a lot of discussion about the outcome. It’s of course difficult to do cross-trial comparisons, but maybe if we have more solid data we can define is there one of the two oral regimens maybe a little bit better than the other one.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Miltenyi: Consultancy; MSD: Consultancy, Speakers Bureau; Hoffmann-La Roche: Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Kite: Consultancy, Speakers Bureau; BeiGene: Consultancy, Research Funding, Speakers Bureau; Roche: Research Funding, Speakers Bureau; AbbVie: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Research Funding, Speakers Bureau; Lilly: Consultancy.
